CClinicalTrials.gg
RecruitingNCT03320759Updated Mar 28, 2024

Enhancing Recovery in Non-Traumatic Spinal Cord Injury

An interventional study of Occupational therapy rehabilitation in Spinal Cord Compression, Spinal Cord Injuries and Cervical Spondylosis, sponsored by Western University, Canada. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Western University, Canada · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigators have spent the last decade uncovering unique metabolic and functional abnormalities in the brains of patients with spinal cord compression. Degenerative spinal cord compression represents a unique model of reversible spinal cord injury. In the investigator's previous work, they have demonstrated that cortical reorganization and recruitment is associated with metabolic changes in the brains of patients recovering from spinal cord compression and is correlated with recovery and improved neurological scores.

The goal of this study is to combine a rigorous platform of clinical care that includes preoperative evaluation, surgery, and rehabilitation, with state of the art imaging techniques to demonstrate how rehabilitative therapy can increase brain plasticity and recovery of neurological function in patients with spinal cord injury. Neurological function will be carefully evaluated in two groups of patients, those receiving rehabilitation and those not receiving rehabilitation after spine surgery, and will be correlated with the results of advanced imaging.

02

Conditions studied

  • Spinal Cord Compression
  • Spinal Cord Injuries
  • Cervical Spondylosis
  • Myelopathy Cervical
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • right-handed
  • have a history of progressive neurological deficits \<24 months
  • eligible for MRI scanning

Exclusion criteria

Exclusion Criteria:

  • having any other neurological disorder or systemic disease that can impair neurological function
  • not fluent in reading and speaking English
  • being claustrophobic
  • unable to follow simple task instructions and maintain standardized movements
  • being unable to return for all follow-up imaging and rehabilitation sessions
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    No rehabilitation
  • Experimental
    Rehabilitation

    Behavioral: Occupational therapy rehabilitation

Interventions

  • BehavioralOccupational therapy rehabilitation

    Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.

05

What researchers measure

Primary outcomes

  1. Changes in levels of N-acetylaspartate (NAA) in the motor cortex

    It is expected that the group of patients receiving rehabilitation will experience less decline in NAA concentrations as compared to the second group of patients not receiving rehabilitation.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  2. Changes to volume of activation in motor and supplementary motor cortices

    Volume of activation is measured by calculating the voxel number within our selected cortical regions, the motor cortex and supplementary motor cortex, using functional magnetic resonance imaging (fMRI). Changes in these numbers demonstrate volume of cortical activation changes in these regions. Following rehabilitation, the investigators expect that the volume of cortical activation of patients, expressed as voxel number, will change between time points compared with changes observed in the control group.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  3. Changes in Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) scores

    Graded Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP) is an indicator of dorsal and palmar sensation, strength (by myotome) and prehension (grasping). GRASSP is a standardized measure to assess hand function in ways that are meaningful in the context of a patient's overall ability to complete activities of daily living.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  4. Changes to intensity of cortical activation in motor and supplementary motor cortices

    Intensity of cortical activation is expressed as signal intensity in beta weights. Following rehabilitation, the investigators expect that the intensity of cortical activation in participants in the intervention group will change between time-points compared with changes observed in the control group.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

Secondary outcomes

  1. RAND Short form (SF)-36 Health Survey Questionnaire

    General health status self-administered evaluation tool. Better scores in the intervention group are expected. Composite score will be reported. The range for this score is from 0 to 100, with 100 indicating the best general health status possible. Subscale scores also range from 0-100 and are simply an average of the scores for each of their relevant questions. Subscales are combined into a composite score by averaging results of all subscales, which is the methodology specified by the creators of the scale (RAND).

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)]

  2. Modified Japanese Orthopaedic Association (mJOA) scale

    A clinical tool used to evaluate impairment due to cervical spondylotic myelopathy, including loss of sensation, motor abilities in limbs, and bowel and bladder control. The lowest possible score is a 0 and the highest, 18. Higher numbers indicate better functioning. Item scores are simply summed to arrive at the composite score.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  3. Myelopathy Disability Index (MDI)

    This self-administered questionnaire is used to measure the degree to which myelopathy has affected the participant's ability to perform activities of daily living. Raw scores will be calculated for each participant and may range from 0 to 30. To arrive at the participant's raw score, item scores are simply summed. The final scores used for analysis will be the participant's score expressed as a percentage. Higher scores indicate greater impairment.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  4. American Spinal Injury Association (ASIA) Impairment Scale

    A clinical assessment tool used to classify motor and sensory impairment in persons with myelopathy. Subscales to be reported include the right and left motor scores (range=0-50 for both) and the right and left sensory scores (range=0-60 for both). Higher scores indicate less impairment.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

  5. Strength as tested with hand dynamometer

    A device used to measure grip strength.

    Time frame: Measured and reported for all follow-ups throughout study (i.e. pre-operatively, 4 weeks, 6 weeks, 6 months)

06

Study locations

1 of 1 sites recruiting
  • LHSC - University Hospital
    London, Ontario N6A 5A5, Canada
    Recruiting
07

Registry details

Key details

Study ID
NCT03320759
Lead sponsor
Western University, Canada
Responsible party
Sponsor
First posted
Oct 25, 2017
Start date
Aug 21, 2018
Primary completion
Dec 1, 2025 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Mar 28, 2024

Study contacts

Sarah Detombe, PhD
Contact
sarah.detombe@lhsc.on.ca
5196858500 ext. 35456

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion